Monkeypox and drug repurposing: seven potential antivirals to combat the viral disease-Reference-Cited by-同舟云学术

Monkeypox and drug repurposing: seven potential antivirals to combat the viral disease

Published:2023-02-22 Issue:0 Volume:0 Page:
ISSN:0048-7554
Container-title:Reviews on Environmental Health
language:en
Short-container-title:

Author:

Varghese Ryan¹²^ORCID,Patel Pal³^ORCID,Kumar Dileep¹⁴⁵^ORCID,Sharma Rohit⁶^ORCID

Affiliation:

1. Poona College of Pharmacy , Bharati Vidyapeeth (Deemed to be) University , Pune Maharashtra , India

2. Department of Clinical Pharmacology , Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre , Kharghar , Navi Mumbai , India

3. Department of Genetic Engineering , College of Engineering and Technology, SRM Institute of Science and Technology , Kattankalathur , Tamil Nadu , India

4. Department of Entomology , University of California , Davis , CA , USA

5. UC Davis Comprehensive Cancer Center , University of California , Davis , CA , USA

6. Department of Rasa Shastra and Bhaishajya Kalpana , Faculty of Ayurveda , Institute of Medical Sciences, Banaras Hindu University , Varanasi , Uttar Pradesh , India

Abstract

Abstract The growing concern about the monkeypox (Mpox) virus infection has garnered a lot of public attention. However, the treatment options available to combat the same is limited to tecovirimat. Additionally, in a possible incidence of resistance, hypersensitivity, or adverse drug reaction, it is imperative to devise and reinforce the second-line therapy. Thus, in this editorial, the authors suggest seven antiviral drugs that could potentially be repurposed to combat the viral illness.

Publisher

Walter de Gruyter GmbH

Subject

Public Health, Environmental and Occupational Health,Pollution,Health (social science)

Link

https://www.degruyter.com/document/doi/10.1515/reveh-2023-0001/pdf

Reference12 articles.

1. Adler, H, Gould, S, Hine, P, Snell, LB, Wong, W, Houlihan, CF, et al.. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022;22:1153–62. https://doi.org/10.1016/s1473-3099(22)00228-6.

2. Desai, AN, Thompson, GR, Neumeister, SM, Arutyunova, AM, Trigg, K, Cohen, SH. Compassionate use of tecovirimat for the treatment of monkeypox infection. JAMA 2022;328:1348. https://doi.org/10.1001/jama.2022.15336.

3. Thornhill, JP, Barkati, S, Walmsley, S, Rockstroh, J, Antinori, A, Harrison, LB, et al.. Monkeypox virus infection in humans across 16 countries — april–june 2022. N Engl J Med 2022;387:679–91. https://doi.org/10.1056/nejmoa2207323.

4. Guarner, J, del Rio, C, Malani, PN. Monkeypox in 2022—what clinicians need to know. JAMA 2022;328:139. https://doi.org/10.1001/jama.2022.10802.

5. Kozlov, M. How does monkeypox spread? What scientists know. Nature 2022;608:655–6. https://doi.org/10.1038/d41586-022-02178-w.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co‐infections and immune‐evading viral hybrids: A perspective;Health Science Reports;2024-01

2. PDE5 inhibitors: breaking new grounds in the treatment of COVID-19;Drug Metabolism and Personalized Therapy;2023-08-24

3. PDE5 inhibitors: breaking new grounds in the treatment of COVID-19;Drug Metabolism and Personalized Therapy;2023-08-24

4. Emerging evidence on Monkeypox: resurgence, global burden, molecular insights, genomics and possible management;Frontiers in Cellular and Infection Microbiology;2023-04-19

5. Hospitalization risk among patients with Mpox infection—a propensity score matched analysis;Therapeutic Advances in Infectious Disease;2023-01